The global orthopedic biomaterials market size was USD 15.5 Billion in 2022 and is likely to reach USD 38.7 Billion by 2031, expanding at a CAGR of 10.4% during 2023–2031. The market growth is attributed to the increasing number of patients opting for joint-related orthopedic procedures.
The rising geriatric population and incidence of musculoskeletal disorders upsurge the demand for orthopedic surgeries as geriatric patients take longer to heal fractures than young adults. Orthopedic surgeons offer more comprehensive treatment for the special needs of the geriatric population.
- As per the United Nations Department of Economic and Social Affairs, World Population Prospects 2022, the global population aged 65 years or above is expected to increase from 10% in 2022 to 16% in 2050. Nearly 40% of the geriatric population is diagnosed with musculoskeletal diseases, whereas 75% of musculoskeletal diseases are reported in persons under the age of 65 years. Moreover, chronic problems faced by the elderly population are related to joint movements.
- In July 2022, the World Health Organization (WHO) identified nearly 1.71 billion people with musculoskeletal conditions globally. Musculoskeletal conditions cause disability with low back pain, hamper well-being, dexterity, and mobility, typically leading to early retirement from work.
Orthopedic biomaterials are artificial supporting materials used for joint replacement, reinforcement for fractures, spinal supportive products, and arthroscopy implant materials. They provide enhanced biocompatibility with the human body and instant relief from pain. Advancements in orthopedic biomaterials facilitate the regeneration or replacement of living tissue. For instance,
- In October 2021, Osfirm granted Whitlockite Biomaterial, an implantable material ideal for sites of bone defects or fractures. In addition, it is a type of magnesium tricalcium phosphate with reconstructive and bioactive regenerative properties, including biocompatibility.
Biomaterial implants lend support for knee, joint, and hip troubles. Biomaterials are used as implants for treating musculoskeletal ailments of muscles, tendons, bones, cartilage, joints, and ligaments. Modernized medical research methodology has made it possible to provide one-time solutions for orthopedic ailments.
The research report finds that the COVID-19 pandemic adversely affected the global orthopedic biomaterials market. The demand for orthopedic biomaterials reduced considerably during the pandemic due to decreased footfalls of patients worldwide for orthopedic treatments.
Several governments worldwide implemented a nationwide lockdown to curb the spread of the virus and restricted public and private transportation, resulting in few road injuries and accidents.
Clinics and hospitals conducted only emergency surgeries and focused on COVID-19 disease treatment. Non-essential expenses by consumers were reduced significantly with the changes in economic conditions and budgets of individuals during the pandemic.
Orthopedic Biomaterials Market Dynamics
Major Drivers
Rising sports activities around the world are boosting the number of young athletes. A flip side of the increased sporting activities has been a proportional upsurge in sports injuries. Sports injuries, including stress fractures and pulled muscles, are commonly treated through sports medicine.
Thus, the rising number of sports and knee injuries and the growing use of biomaterials in sports medicine are expected to drive the market in the coming years. For instance,
-
In 2021, as per the report of the National Safety Council in America, injuries reported from exercise and exercise equipment were 377,939, injuries from bicycles and accessories were 425,910, and injuries reported from ATVs, minibikes, mopeds, and others were 229,974. While 217,646 injuries were reported from skateboards, scooters, and hoverboards.
-
In June 2021, according to the report published by the Canadian Institute of Health Information, Knee replacement surgeries are among the top three inpatient surgeries performed per year in Canada.
-
In June 2022, the US FDA Administration approved a novel ceramic total knee replacement device by CeramTec. It is expected to effectively diagnose and treat irreversible debilitating and life-threatening conditions or diseases.
Existing Restraints
Implanted orthopedic materials can be rejected by the body, causing strong allergic reactions. This factor is expected to hamper market growth in the coming years. Surface contamination of implants is responsible for spreading infections in the implant area.
Reaction indications ranging from rashes to swellings have restrained the wide use of biomaterials. Cases of implanted material intolerance by the human body have been found, causing severe joint pain, tissue edema, and recurring effusion.
Soreness and stiffness in joints have been reported as well. This is a major reason that is anticipated to hamper the progress of the orthopedic biomaterials market.
Moreover, limited reimbursement policies for premium products and orthopedic implants in developing countries are anticipated to fuel the market during the forecast period. Reimbursement policies pressure manufacturers to lower the prices for these materials.
Emerging Opportunities
Rising investments in research & development generate opportunities for introducing advanced biomaterial products. Major companies in healthcare manufacturing invest heavily in R&D to introduce better treatment resources for their consumers.
Manufacturers focus on developing technologically advanced products that give market players an edge over their competitors with increased revenue growth. Introduction of next-generation orthopedic biomaterials for various orthopedic procedures provides a significant market expansion opportunity. For instance,
-
In March 2023, Invibio Biomaterial Solutions declared the launch of PEEK-OPTIMA™ AM Filament. It is an implantable PEEK polymer specially designed for additive manufacturing.
-
In March 2022, Synergy Biomedical, LLC introduced BIOSPHERE FLEX SP EXTREMITIES, Synthetic Bioactive Bone Graft. This sheet putty is produced from a porous collagen/sodium hyaluronate carrier and innovative spherical bioactive glass granules.
Scope of Orthopedic Biomaterials Market Report
The global orthopedic biomaterials market research report includes an assessment of the market trends, market segments, and regional analysis of markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Orthopedic Biomaterials Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Material (Ceramics & Bioactive Glasses, Metal, Calcium Phosphate Cement, Polymers, and Others), Application (Bio-resorbable Tissue Fixation, Orthopedic Implants, Joint Replacement/Reconstruction, Orthobiologics, Viscosupplementation, and Others), and End-user (Specialty Clinics, Hospitals, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Orthopedic Biomaterials Market Size and Analysis, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Invibio Ltd; DSM; Globus Medical; Zimmer Biomet; Evonik Industries AG; Stryker; Exactech, Inc.; Smith+Nephew; Bioventus; Mitsubishi Chemical America, Inc.; CAM Bioceramics B.V.; Heraeus Holding; Medtronic; DJO, LLC; Arthrex, Inc. and NuVasive®, Inc.
|
Orthopedic Biomaterials Market Segment Insights
Material Segment Analysis
Based on material segment, the global orthopedic biomaterials market is classified into ceramics & bioactive glasses, metal, calcium phosphate cements, polymers, and others. The ceramics & bioactive glasses segment is expected to dominate the market during the projection period owing to the rapid adoption of ceramics in various procedures for repairing hard tissues.
Bioavailability and better efficiency of ceramics & bioactive glass material in orthopedics are expected to support the segment growth. Interbody synthesis, joint reconstruction, and spine reconstruction surgeries use ceramics & bioactive glasses implant materials.
Increased use of pedicle screws and synthetic cages for fixation procedures drives the segment’s growth. Synthetic cages and pedicle screws are used in interbody cages in spinal surgeries that warrant disc removal for interbody fusion procedures. Bioinert ceramics, specifically alumina, are largely preferred in hip and joint arthroplasty.
The polymer segment is anticipated to expand rapidly in the coming years due to its favorable biodegradable properties. According to clinical criteria, implant materials should not generate any by-products that could harm the human body or be rejected by it.
Biodegradable polymers from the family of hydroxy esters are used in surgical procedures. They include polyglycolic acid (PGA), polylactic acid (PLA), and copolymers (PLGA). Polymer usage in joint-related orthopedic procedures such as arthroplasties and bone void filling is increasing. The usage in the form of bone cement and load-bearing surfaces is expected to boost segment growth.
Application Segment Analysis
On the basis of application, the market is segmented into bio-resorbable tissue fixation, orthopedic biomaterial implants, joint replacement/reconstruction, orthobiologics, viscosupplementation, and others.
The orthopedic implants segment is expected to expand significantly during the projected period with increasing applications in bone fracture fixations and degenerative disc conditions.
Biomaterials with superior load-bearing surfaces and capacities coupled with high corrosion resistance are in high demand due to the ductility, strength, and wear resistance. The orthobiologics segment is projected to grow rapidly in the coming years owing to the increasing number of orthopedic surgeries for bone and joint reconstruction worldwide.
Orthobiologics are materials derived biologically for regeneration. The rising number of obese patients and increasing incidences of traumatic events support segment growth.
Orthobiologics procedures help the human body heal faster through the injection of substances by using body cells. Healing of ligament and tendon injuries can be expedited through orthobiologics to protect from osteoarthritis.
End-user Segment Analysis
Based on end-user segment, the market is segmented into specialty clinics, hospitals, and others. The hospitals segment is expected to grow at robust growth rate during the forecast period, due to rising number of bone and joint-related orthopedic procedures in numerous countries.
Elderly people require orthopedic biomaterial implants in knee replacements, joints, ligaments, and tendons. Such corrective implanting procedures are possible in hospitals which are expected to boost segment growth.
The specialty clinics segment is projected to expand rapidly in the coming years owing to the advantages of catering to specific orthopedic ailments of the muscles, joints, and bones. Biomaterials are widely used for diagnostics and engineering in skeletal, muscle, and tissue. Bone fixation materials made out of biomaterials are growing rapidly and are expected to boost segment expansion.
Regional Analysis
In terms of region, the global orthopedic biomaterials market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projected period, due to the well-established healthcare infrastructure in the region.
Moreover, the rising demand from surgeons for technologically advanced implants with warranty and average vending price of orthopedic implants is projected to fuel the market.
The market of Asia Pacific is anticipated to expand rapidly during the forecast period due to the growing number of individuals with joint and knee disorders in the region. Furthermore, rising government initiatives for biomaterial usage awareness and rapid expansion of medical facilities are further boosting the market in the Asia Pacific.
Segments
The global orthopedic biomaterials market has been segmented on the basis of
Material
- Ceramics & Bioactive Glasses
- Metal
- Calcium Phosphate Cement
- Polymers
- Others
Application
- Bio-resorbable Tissue Fixation
- Orthopedic Implants
- Joint Replacement/Reconstruction
- Orthobiologics
- Viscosupplementation
- Others
End-User
- Specialty Clinics
- Hospitals
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Invibio Ltd
- DSM
- Globus Medical
- Zimmer Biomet
- Evonik Industries AG
- Stryker
- Exactech, Inc.
- Smith+Nephew
- Bioventus
- Mitsubishi Chemical America, Inc.
- CAM Bioceramics B.V.
- Heraeus Holding
- Medtronic
- DJO, LLC
- Arthrex, Inc.
- NuVasive®, Inc.
Competitive Landscape
Key players competing in the orthopedic biomaterials industry are Invibio Ltd; DSM; Globus Medical; Zimmer Biomet; Evonik Industries AG; Stryker; Exactech, Inc.; Smith+Nephew; Bioventus; Mitsubishi Chemical America, Inc.; CAM Bioceramics B.V.; Heraeus Holding; Medtronic; DJO, LLC; Arthrex, Inc. and NuVasive®, Inc.
Some of the major players in the market have adopted different organic growth strategies to expand manufacturing units and witness significant growth.
The rising awareness regarding inexpensive orthopedic treatments using biomaterials provides quick relief to patients and adds new consumers. Competent treatment offerings provide valuable prospects for market growth.
Governments worldwide and private organizations related to economic and social affairs are creating awareness about using orthopedic biomaterials. Further, clinical trials have developed inquisitive interest amongst the masses, creating opportunities for investments in the market. For instance,
- On 10 February 2022, DePuy Synthes, an orthopedic unit of US healthcare giant Johnson & Johnson, acquired US-based foot and ankle company CrossRoads Extremity Systems. This company manufactures implants and instruments for certain foot and ankle surgeries.
- On 01 December 2020, Zimmer Biomet, a global solution provider for musculoskeletal disorders based in the US, acquired A&E Medical and its complete portfolio of sternal closure devices, including sternal sutures, cable systems, rigid fixation, punch products, and pacing wires.
Request For Customization
Enquiry Before Buying
Speak With Analyst
